In one paragraphArticle in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
18 authors.
Nancy T SantiappillaiCell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-9797-559X Celia Martínez de la TorreCell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-5088-3839 Marjan BerishajCell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Michelle SaoiThe Donald B. and Catherine C. Marron Cancer Metabolism Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-7678-6239 Justin R CrossThe Donald B. and Catherine C. Marron Cancer Metabolism Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MLeveraging fructose transport to create a privileged substrate to selectively fuel T cellsR01CA248364 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Kayvan R Keshari · 2021 to 2026
$4.3MDevelopment of large-field-of-view hyperpolarized MRIR01CA237466 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CUNNINGHAM, CHARLES H., HRICAK, HEDVIG · 2020 to 2024
$3.4MVisualizing oxidative stress using hyperpolarized magnetic resonanceR01CA252037 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI KESHARI, KAYVAN R · 2020 to 2024
$3.3MInterrogation of the oxidative-stress-induced leukemia program in vivo usingmetabolic imagingR01CA283578 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Kayvan R Keshari, Michael Kharas · 2023 to 2026
$3.0MRethinking the "quiet" nature of apoptotic cell clearance.DP2GM146337 · NIGMS · SLOAN-KETTERING INST CAN RESEARCH · PI PERRY, JUSTIN S · 2021 to 2024
$2.6MImage-guided Trp-IDO/TDO-Kyn-AHR pathway inhibition, combined with immunotherapyR01CA249294 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI KESHARI, KAYVAN R, MERGHOUB, TAHA · 2021 to 2025
$2.6MRegulation of tumor-associated phagocyte physiology during tumor cell clearanceR00CA237728 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI PERRY, JUSTIN S · 2019 to 2021
$747kImmunology and Microbial Pathogenesis Research Training ProgramT32AI134632 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI EHRT, SABINE, LI, MING · 2019 to 2023
$747kUsing [6-13C,6-15N3]-L-Arginine for the molecular imaging of in vivo tumor arginase flux, and towards understanding the role of arginase isoforms in cancer metabolism.F30CA225174 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI CHO, ANDREW · 2018 to 2021
$175kUnderstanding how appropriate apoptotic cell degradation ensures lung homeostasisF31HL182129 · NHLBI · SLOAN-KETTERING INST CAN RESEARCH · PI Achuth Nair · 2025 to 2026
$100kNCI NIH HHS F30 CA225174NCI NIH HHS P30 CA008748NCI NIH HHS R00 CA237728NCI NIH HHS R01 CA237466NCI NIH HHS R01 CA248364NCI NIH HHS R01 CA249294NCI NIH HHS R01 CA252037NCI NIH HHS R01 CA283578NHLBI NIH HHS F31 HL182129NIAID NIH HHS T32 AI134632NIGMS NIH HHS DP2 GM146337
6 · The paper itselfAbstract
Triple-negative breast cancer (TNBC) develops in hypoxic, nutrient-limited tumors enriched with macrophages and cell death. We show that metabolically distinct TNBCs differentially exploit macrophage-derived nutrients, influencing tumor growth and therapeutic response. Prolonged hypoxia reprogrammed mouse and human macrophages, enabling them to release metabolites that rescued the growth of select TNBC cell lines during glutamine deprivation or glutamine metabolism inhibition. Hypoxic macrophages reduced glutamine consumption, increased arginine utilization, and secreted higher levels of ornithine, an intermediate of arginine metabolism. Exogenous ornithine, but not arginine, restored the growth of responsive TNBC cells. Mechanistically, TNBC cells diverted ornithine into proline biosynthesis, supporting oxidative pentose phosphate pathway activity. In vivo, depletion of tumor-associated myeloid cells reduced tumor growth and impaired proline synthesis in glutaminase inhibitor-resistant TNBC. These findings identify hypoxia-driven metabolic cross-talk between macrophages and TNBC cells, revealing ornithine-dependent proline metabolism as a mechanism by which macrophages sustain tumor growth under nutrient stress and contribute to resistance to glutamine-targeted therapies.
Indexed as
MacrophagesNutrientsStress, PhysiologicalTriple Negative Breast NeoplasmsAnimalsArginineCell Line, TumorCell SurvivalFemaleGlutamineHumansMetabolic ReprogrammingMiceOrnithineProlineArginineGlutamineOrnithineProline
Identifiers
PMID42826203
PMCPMC13632722
What Socratic holds
Textmetadata
Read underepoch 390